Targeting CD47 for cancer immunotherapy

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhongxing, Sun, Hao, Yu, Jifeng, Tian, Wenzhi, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557524/
https://www.ncbi.nlm.nih.gov/pubmed/34717705
http://dx.doi.org/10.1186/s13045-021-01197-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557524/
https://www.ncbi.nlm.nih.gov/pubmed/34717705
http://dx.doi.org/10.1186/s13045-021-01197-w

Ejemplares similares